Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S&P lowers NBTY credit rating

This article was originally published in The Tan Sheet

Executive Summary

Standard & Poor's lowers the vitamin and supplement maker's credit rating from 'BB' to 'B+' in light of the Carlyle Group's planned acquisiton. The change "reflects weakened credit measures" from Carlyle's proposed capital structure for NBTY, including about $2 billion in additional debt, analyst Jacqueline Hui said in an Aug. 26 release. But the rating service deemed NBTY "stable," saying the company likely will "maintain pro forma credit metrics in line with the current rating over the near term." NBTY remains in a strong market position, but the supplement market is highly competitive, S&P noted. Carlyle announced its $3.8 billion acqusition July 15 (1"The Tan Sheet" July 19, 2010)

You may also be interested in...



Carlyle Group's $3.8B Bid For NBTY Could Face Competition

The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant

Pharma Could Face Fewer False Claims Act Suits If Supreme Court Concurs With Government

High court is to determine whether the government can dismiss an FCA complaint after initially declining to take it over. In recent years, the government has dismissed numerous qui tam suits against pharma companies in which it did not intervene.

Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard

Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel